AstraZeneca
AZN · NASDAQ · Healthcare
$163.33
$4.64 (-2.84%) today
Market Cap
$253.31B
24h Volume
$385.6M
P/E Ratio
24.4
52w High
$208.62
52w Low
$145.54
Est. AI Revenue
8%
7-Day Sparkline (Static)
Company facts
Performance
About AstraZeneca
AstraZeneca is a global pharmaceutical company. It makes money selling prescription medicines across oncology, cardiovascular, and rare diseases, backed by a research pipeline that feeds new drug launches.
AI works inside its R&D machine: an AI drug discovery platform helps identify candidates, clinical trial AI improves study design, precision medicine AI matches treatments to patients, and biomarker analytics find the biological signals that guide development.
Founded in 1999 and headquartered in Cambridge, United Kingdom, AstraZeneca trades on the NASDAQ and employs about 96,100 people.
AstraZeneca in the AI buildout
AstraZeneca sits in the AI Healthcare layer of the buildout as an adopter rather than a supplier. AI in discovery, trial design, and precision medicine may raise pipeline odds over time, which is why it invests. Value is still driven by drug launches and patents rather than AI demand, so Supercycle scores its AI exposure at 8 out of 100.
AZN is tracked in AI Healthcare, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
AZN trades at $163.33, 28% of the way up its 52-week range of $145.54 to $208.62.
Market cap
Market capitalization is $253.31B, with an AI Exposure Score of 8 out of 100.
Valuation vs peers
Its P/E ratio of 24.4 is below the AI Healthcare category median of 29.6.
Next earnings
AstraZeneca is next expected to report earnings on October 30, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does AstraZeneca do?
AstraZeneca develops and sells prescription medicines, with strength in oncology, cardiovascular, and rare diseases. Its revenue comes from drugs sold globally, supported by a research pipeline of new therapies.
How is AstraZeneca exposed to AI?
Peripherally. AI supports drug discovery, trial design, and precision medicine as a productivity tool that may raise pipeline odds, while value follows launches and patents. Supercycle gives it an AI Exposure Score of 8 out of 100.
What are AstraZeneca's main AI capabilities?
An AI drug discovery platform, clinical trial AI design tools, precision medicine AI that matches treatments to patients, and biomarker AI analytics that guide drug development decisions.
Where is AstraZeneca headquartered and who leads it?
AstraZeneca is headquartered in Cambridge, United Kingdom, and led by CEO Pascal Soriot. The company was founded in 1999, employs about 96,100 people, and its shares trade on the NASDAQ.
Is AZN a pure play AI stock?
No. AstraZeneca is a pharmaceutical company that applies AI inside research and development. With an AI Exposure Score of 8 out of 100, it sits near the low end of the AI Exposure leaderboard.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.